Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Eisai Inaugurates Parenteral Facility In North Carolina
Eisai said that its 65,000sqft facility is expected to serve as Eisai’s global commercial manufacturing and drug development site for intravenous drug products in support of the company’s
Eisai said that its 65,000sqft facility is expected to serve as Eisai’s global commercial manufacturing and drug development site for intravenous drug products in support of the company’s
Mr Mills joins Qualitest Pharma from Columbia Laboratories, where he was CEO and president. He previously held senior management positions at Watson Pharmaceuticals, Schein Pharmaceuticals and Alpharma. Marvin
Reportedly, the eight-month research program is coupled with an exclusive license to genOway for the rodent transgenic business. The research program aims at establishing germline transmission in rats
Reportedly, the licensing is part of the Advaxis’ 20-year exclusive worldwide license agreement with UPenn. It covers patents that expire as late as 2023. As per the terms
SCPMG is expected to join Quintiles’ three other prime sites into clinical research. Clinical research professionals from both Quintiles and SCPMG are expected to work together closely to
Dr Mansour has spent nearly 25 years in the life sciences industry with positions at Biochem Pharma and Wyeth Pharmaceuticals. His most recent position at Wyeth Research was
i3’s customers are expected to benefit from ChinaGate’s expertise in overseeing clinical trials, submitting filings, obtaining licenses and navigating the regulatory process. ChinaGate’s customers will gain access to
Weikang Bio-Technology Group has posted a net income of $4.54m for the first quarter 2010, or $0.17 per diluted share, compared to $3.8m, or $0.15 per diluted share,
Forest Labs and Nycomed claimed that if approved, roflumilast, a once-a-day oral tablet, will be the first in a new class of treatment for COPD. Roflumilast is not
The randomised, double-blind, placebo-controlled, parallel-group, Phase II study was conducted in 25 centers across US, Canada, Europe and Israel and included 559 patients with ALS. In the trial,